Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited develops clinical-stage oncology therapies through an Australian foreign-issuer structure whose American depositary shares trade under KZIA. Company news centers on paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor being developed across brain cancer and advanced breast cancer indications, including triple-negative breast cancer studies that report clinical and translational findings.
Recurring updates also cover Kazia's broader oncology platform, including NDL2, a PD-L1 protein degrader platform, and MSETC, a SETDB1-targeted epigenetic program. Additional company developments include research leadership, licensing activity, financing and capital-structure actions, Nasdaq listing compliance, annual meeting matters, governance changes, and operating or financial results.
Kazia Therapeutics (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1, 2026. He brings more than 20 years of investment banking and biotech leadership experience.
Levine has held senior roles at Cardiff Oncology, Cidara Therapeutics, Verenium, Sapphire Energy, and Goldman Sachs, supporting financings and strategic transactions.
Kazia Therapeutics (NASDAQ: KZIA) plans to expand its ongoing Phase 1b trial of paxalisib in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients. The study combines paxalisib with pembrolizumab and chemotherapy.
The larger cohort aims to better characterize safety, tolerability, dose optimization, and preliminary efficacy, including ORR, PFS, and translational biomarkers. Kazia attributes the expansion to encouraging safety, tolerability, and clinical activity data and expects further clinical updates through 2026 and into 2027.
Kazia Therapeutics (NASDAQ: KZIA) appointed Dr. Sudha Rao as Chief Scientific Officer on April 15, 2026. Dr. Rao brings 20+ years of translational epigenetics experience, authorship on high‑impact journals, and lead inventorship on 39 international patents to advance Kazia's integrated oncology platform including paxalisib, NDL2, and MSETC.
She will lead R&D, biomarker strategy, external collaborations, and platform expansion with AI‑guided discovery and spatial/liquid epigenetic precision medicine.
Kazia Therapeutics (Nasdaq: KZIA) has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, including the lead candidate MSETC and an AI-integrated discovery engine. The program is in preclinical development with a planned IND-enabling path.
Management expects to advance the SETDB1 and PD-L1 degrader programs to IND readiness for approximately $6 million over 18 months, with an upfront payment of $1.39 million and a tiered revenue-sharing structure.
Kazia Therapeutics (NASDAQ: KZIA) reported preclinical and translational data for NDL2, a bicyclic peptide degrader designed to selectively remove nuclear PD-L1, an intracellular driver of immunotherapy resistance and metastasis. In murine TNBC models NDL2 reduced tumor volume by 49% as monotherapy and 73% with anti-PD-1, plus a 50% reduction in lung metastases in combination. Data show immune reprogramming, favorable preclinical safety/PK, and liquid biopsy biomarker evidence. IND-enabling studies are underway with first-in-human trials targeted for 2027 and a planned dataset presentation in Q2 2026.
Kazia Therapeutics (NASDAQ: KZIA) reported preliminary clinical responses from its ongoing Phase 1b study of paxalisib combined with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer (TNBC). To date, three patients treated with paxalisib-based regimens showed meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response under expanded access. Median time on treatment is ~6.1 months, all patients remain on therapy, and paxalisib at 30 mg daily showed generally favorable tolerability. The company plans additional site activations and targets 12 TNBC patients by end-2026 with topline data in early 2027.
Kazia Therapeutics (NASDAQ: KZIA) said CEO John Friend will attend J.P. Morgan Healthcare Conference week and meet investors and partners.
The company highlighted it is well capitalized after a recent financing and expects a clinical and translational update before month-end from its Phase 1b paxalisib trial in advanced triple-negative breast cancer (TNBC), including additional clinical responses and expanded circulating tumor cell (CTC) and CTC cluster biomarker analyses. Kazia also plans the first update on its PD-L1 protein degrader program.
Kazia Therapeutics (NASDAQ: KZIA) regained full compliance with all Nasdaq listing standards on Dec 18, 2025 after Nasdaq confirmed the company meets Listing Rule 5550(b)(1) (the $2.5 million minimum stockholders' equity alternative to MVLS).
The restoration follows a $50 million private placement led by healthcare institutional investors that the company says materially strengthened its balance sheet; the previously scheduled Nasdaq hearing was cancelled as moot and Kazia's ADS will continue trading on The Nasdaq Capital Market.
Kazia Therapeutics (NASDAQ: KZIA) reported translational and early clinical data (Dec 10, 2025) showing paxalisib activity across HER2+ and triple‑negative breast cancer.
Key findings: an early TNBC patient showed ~76% primary tumor volume shrinkage and reversal of CD8 T‑cell exhaustion; ex vivo HER2+ samples showed paxalisib reduced single circulating tumor cells (CTCs) by 42% and CTC clusters by 78%; resumption after a 3‑week pause re‑suppressed CTC clusters, indicating a direct pharmacodynamic effect. Data support paxalisib's potential to disrupt mesenchymal, metastatic CTC clusters and to reinvigorate anti‑tumor immunity, informing combination strategies with pembrolizumab, PARP inhibitors, and chemotherapy.
Kazia Therapeutics (NASDAQ: KZIA) announced a private placement (PIPE) offering of approximately $50.0 million of ordinary shares and pre-funded warrants at an ADS-equivalent price of $5.00 per ADS (one ADS = 500 ordinary shares). The financing is led by healthcare-dedicated investors and expected to close on December 3, 2025, subject to customary conditions.
Net proceeds are expected to be about $46.5 million after fees and expenses, intended to fund continued clinical development of paxalisib, advance the PD-L1 degrader program, and for general corporate purposes; cash runway is expected into the second half of 2028.